Skip to main content
Fig. 3 | BMC Cardiovascular Disorders

Fig. 3

From: Combining genetic proxies of drug targets and time-to-event analyses from longitudinal observational data to identify target patient populations

Fig. 3

Effect of PCSK9 rs11591147 on time to cardiovascular (CV) death/heart transplant from first ischemic heart disease diagnosis (IHD) in (a) unmatched and (b) matched participants. Only individuals of European ancestry were included. Individuals with GT/TT genotypes (proxy for PCSK9 inhibitor treatment) showed better survival for CV death/heart transplant compared to individuals with GG genotype (controls)

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us